TreeFrog Therapeutics produces large-scale Parkinson's cell therapy in a bioreactor, achieving full recovery in pre-clinical models.
TreeFrog Therapeutics has reported the first successful large-scale production of a Parkinson's disease cell therapy in a bioreactor, as detailed in the Neurotherapeutics Journal. The study achieved full behavioral recovery in pre-clinical models after 16 weeks of transplantation using a unique 3D microtissue format. This innovative approach addresses previous industrialization challenges and offers a promising solution for patients, potentially enabling the treatment of hundreds from a single bioreactor.
October 01, 2024
3 Articles